68ga-maa
Small moleculeexperimentalImaging agent
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 31, 2020 (NCT04243824)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 68-gallium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04243824 | Early Phase 1 (Phase 1) | Jan 31, 2020 | BTG, Embolx, Inc., University of North Carolina at Chapel Hill |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BTG | For profit | 1 | 0 | 1 | 2020 |
| Embolx, Inc. | For profit | 1 | 0 | 1 | 2020 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 1 | 1 | 1 | 2020 |
3 organizations
Page 1 / 1